Alternative endpoints to the 5‑year overall survival and locoregional control for nasopharyngeal carcinoma: A retrospective analysis of 2,450 patients

  • Authors:
    • Chen Chen
    • Wei Yi
    • Jin Gao
    • Xiao‑Hui Li
    • Lu‑Jun Shen
    • Bo‑Fei Li
    • Zi‑Wei Tu
    • Ya‑Lan Tao
    • Chang‑Bin Jiang
    • Yun‑Fei Xia
  • View Affiliations

  • Published online on: February 20, 2014     https://doi.org/10.3892/mco.2014.262
  • Pages: 385-392
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The purpose of the present study was to investigate alternative endpoints to the 5‑year overall survival (OS) and locoregional control (LRC) for nasopharyngeal carcinoma (NPC). A total of 2,450 NPC patients were enrolled in this study, including 1,842 patients treated with two‑dimensional (2D) radiotherapy (RT), 451 treated with 3D conformal RT (CRT) and 157 treated with intensity‑modulated RT (IMRT). We sequentially calculated the 1‑, 2‑, 3‑ and 4‑year survival rates using a life table and compared these with the 5‑year survival rate using the McNemar method, with the survival rate of the last indifferent comparison being considered as the alternative endpoint. For 2D RT, stage I patients exhibited similar survival rates at 1 and 5 years (98.9 vs. 94.4%, respectively; P=0.125 for both OS and LRC); stage N3 patients exhibited similar 4‑year OS (55.2 vs. 53.5%; P=1.000) and 2‑year LRC (78.3 vs. 71.2%; P=0.125) to the 5‑year OS and LRC. For IMRT, the 1‑, 2‑, 3‑, 4‑ and 5‑year OS and LRC rates in stage I/II NPC patients were 100, 98, 96, 94 and 94% for OS and 100, 98, 96, 96 and 96% for LRC, respectively. No significant differences were observed for all the comparisons. For stage III/IV NPC patients treated with IMRT, the 1‑, 2‑, 3‑, 4‑ and 5‑year rates were 99.1, 96.3, 92.5, 88.8 and 85.0% for OS and 98.1, 97.2, 95.3, 90.7 and 89.7% for LRC, respectively. Only the 4‑year OS and LRC rates were indifferent from those at 5 years (P=0.125 for OS and P=1.00 for LRC). In conclusion, the 1‑year OS and LRC for stage I NPC patients treated with 2D RT or stage I̸II NPC patients treated with IMRT, the 4‑year OS and 2‑year LRC for stage N3 NPC patients treated with 2D RT and the 4‑year OS and LRC for stage III/IV NPC patients treated with IMRT were determined as the alternative endpoints to the 5‑year OS and LRC for NPC patients.
View Figures
View References

Related Articles

Journal Cover

May-June 2014
Volume 2 Issue 3

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chen C, Yi W, Gao J, Li XH, Shen LJ, Li BF, Tu ZW, Tao YL, Jiang CB, Xia YF, Xia YF, et al: Alternative endpoints to the 5‑year overall survival and locoregional control for nasopharyngeal carcinoma: A retrospective analysis of 2,450 patients. Mol Clin Oncol 2: 385-392, 2014.
APA
Chen, C., Yi, W., Gao, J., Li, X., Shen, L., Li, B. ... Xia, Y. (2014). Alternative endpoints to the 5‑year overall survival and locoregional control for nasopharyngeal carcinoma: A retrospective analysis of 2,450 patients. Molecular and Clinical Oncology, 2, 385-392. https://doi.org/10.3892/mco.2014.262
MLA
Chen, C., Yi, W., Gao, J., Li, X., Shen, L., Li, B., Tu, Z., Tao, Y., Jiang, C., Xia, Y."Alternative endpoints to the 5‑year overall survival and locoregional control for nasopharyngeal carcinoma: A retrospective analysis of 2,450 patients". Molecular and Clinical Oncology 2.3 (2014): 385-392.
Chicago
Chen, C., Yi, W., Gao, J., Li, X., Shen, L., Li, B., Tu, Z., Tao, Y., Jiang, C., Xia, Y."Alternative endpoints to the 5‑year overall survival and locoregional control for nasopharyngeal carcinoma: A retrospective analysis of 2,450 patients". Molecular and Clinical Oncology 2, no. 3 (2014): 385-392. https://doi.org/10.3892/mco.2014.262